-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Equal-Weight on Tvardi Therapeutics, Lowers Price Target to $4

Benzinga·04/01/2026 19:09:01
Listen to the news
Barclays analyst Etzer Darout maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Equal-Weight and lowers the price target from $5 to $4.